Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | AKT1 | P31749 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CDC25A | P30304 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.69 |
| ▸ | PRKCG | P05129 | 1/20 | 0.69 |
| ▸ | PRKCB | P05771 | 1/20 | 0.69 |
| ▸ | PRKCA | P17252 | 1/20 | 0.69 |
| ▸ | PRKCH | P24723 | 1/20 | 0.69 |
| ▸ | PRKCI | P41743 | 1/20 | 0.69 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.69 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.69 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.69 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.69 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10415264 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| Miltefosine SCHEMBL20769827 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL4166195 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL596694 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| Miltefosine SCHEMBL26215 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| Octadecylphosphonocholine SCHEMBL744376 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL29465558 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| Miltefosine SCHEMBL7189058 | 0.98 | LMNA (0.97) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL9234856 | 0.98 | LMNA (0.96) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL10934123 | 0.94 | LMNA (0.88) | LMNAAKT1ESR1ADORA3CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119451386-A | Hole transport layer, perovskite solar cell and preparation method | 天合光能股份有限公司 | 2025-02-14 | — | — | CN | claimed |
| EP-3586142-B1 | DETECTION OF MEMBRANE PROTEINS | UNIV OXFORD INNOVATION LTD (GB) | 2024-12-25 | — | — | EP | claimed |
| CN-111414011-B | Hypersonic aircraft performance-keeping fault-tolerant control method considering fault of actuating mechanism | 中北大学 | 2023-06-30 | — | — | CN | claimed |
| US-8703179-B2 | Mucosal formulation | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2014-04-22 | — | — | US | claimed |
| WO-2007133261-A1 | MUCOSAL FORMULATION | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2007-11-22 | — | — | WO | claimed |
| US-20070264206-A1 | Mucosal formulation | KIMBERLY-CLARK WORLDWIDE, INC. | 2007-11-15 | — | — | US | claimed |
| EP-0108565-A2 | Phospholipids, their production and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1984-05-16 | — | — | EP | claimed |
| US-20260097150-A1 | Implantable Device for Treating an Ocular Condition | CELANESE EVA PERFORMANCE POLYMERS LLC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260096984-A1 | Implantable Device for Administering a Therapeutic Agent | CELANESE EVA PERFORMANCE POLYMERS LLC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260096985-A1 | Injectable Composition For Drug Delivery | CELANESE EVA PERFORMANCE POLYMERS LLC | 2026-04-09 | — | — | US | disclosed |
| EP-4312951-A1 | IMPLANTABLE MEDICAL DEVICE FOR THE DELIVERY OF NUCLEIC ACID-ENCAPSULATED PARTICLES | Celanese EVA Performance Polymers LLC (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-111414011-B | Hypersonic aircraft performance-keeping fault-tolerant control method considering fault of actuating mechanism | 中北大学 | 2023-06-30 | — | — | CN | disclosed |
| WO-2022212300-A1 | IMPLANTABLE MEDICAL DEVICE FOR THE DELIVERY OF NUCLEIC ACID-ENCAPSULATED PARTICLES | CELANESE EVA PERFORMANCE POLYMERS LLC (US) | 2022-10-06 | — | — | WO | disclosed |
| US-20180064813-A1 | Oral Composition for Delivery of Drugs and Other Substances | AVANTI POLAR LIPIDS, LLC | 2018-03-08 | — | — | US | disclosed |
| US-9872908-B2 | Oral composition for delivery of drugs and other substances | AVANTI POLAR LIPIDS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-8703179-B2 | Mucosal formulation | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| WO-2007133261-A1 | MUCOSAL FORMULATION | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070264206-A1 | Mucosal formulation | KIMBERLY-CLARK WORLDWIDE, INC. | 2007-11-15 | — | — | US | disclosed |
| US-4935520-A | ANTITUMOR AND ANTICARCINOGENIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-06-19 | — | — | US | disclosed |
| EP-0108565-A2 | Phospholipids, their production and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1984-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097150-A1 | Implantable Device for Treating an Ocular Condition | P4HTM, ITGAM, TIMM44 | LMNA 3360/4885AKT1 2564/4885ESR1 943/4885 |
| US-20260096984-A1 | Implantable Device for Administering a Therapeutic Agent | GHITM, O60361, P4HTM | LMNA 3525/4885AKT1 1268/4885ESR1 817/4885 |
| US-20070264206-A1 | Mucosal formulation | MUC1, CHMP4B, VMA21 | LMNA 2111/4885AKT1 1224/4885ESR1 1954/4885 |
| US-20260096985-A1 | Injectable Composition For Drug Delivery | SAMM50, OPRM1, IRAK4 | LMNA 3018/4885AKT1 1513/4885ESR1 747/4885 |
| US-20180064813-A1 | Oral Composition for Delivery of Drugs and Other Substances | MGLL, SGMS2, LIPA | LMNA 566/4885AKT1 2899/4885ESR1 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.